



Unicancer and Flatiron Health partner to accelerate regulatory-grade evidence generation from international Real-World Data

Paris, February 5, 2025


Unicancer, a European leader in oncology research that leads ambitious programs in the field of Real-World Data (RWD) as the ESME program and the OncoDataHub program in collaboration with a network of 70 hospitals and Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using RWD today announced a new research partnership to advance Health-Technology Assessment (HTA) decision-making through the use of Real-World Evidence (RWE).

The Challenge of Using Non-Local Real-World Evidence in HTA Decision-Making

HTA bodies generally prioritize evidence generated from local RWD to demonstrate the value of new medicines. However, the scarcity of local data often necessitates consideration of RWE generated from non-local data sources. Furthermore, since evidence on the efficacy and safety of innovative medicines is typically generated through international clinical trials, it is important to understand how and when robust RWE analyses can be conducted for a population using non-local data.

Unicancer and Flatiron Health Collaborate to Advance RWE Transportability for HTA Decision-Making

To overcome this challenge, Unicancer and Flatiron Health will partner to demonstrate the feasibility and the robustness of RWE transportability between US and France in various use cases relevant for HTA decision-making as part of the Flatiron FORUM initiative. Flatiron FORUM (Fostering Oncology RWE Uses and Methods) is a research consortium that includes collaborators from several leading global life science companies. With data from global Real-World Evidence providers and input from HTA experts, the aim is to enable better HTA decision-making through the exemplar use of RWE and research methods with collaborators working together to shape use cases and interpret research findings. Finally, this work should create the conditions for applying the target trial emulation methodology to large real-world databases in order to evaluate the effectiveness of therapeutic strategies based on use cases in oncology.



“This collaboration between Unicancer and Flatiron Health represents a significant step forward in the use of Real-World Evidence to support HTA decision-making. By leveraging international data, we aim to demonstrate the feasibility of generating regulatory-grade evidence and ensure that innovative treatments are evaluated in a more comprehensive and global context.”, as stated by Anne-Laure Martin, Director of Health Data and Partnerships at Unicancer.

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, Real-World Evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Media Contact

Nina Toor - press@flatiron.com

About Unicancer

Unicancer is the only French hospital network 100% dedicated to the fight against cancer. It brings together the 18 French Comprehensive Cancer Centers, non-profit private healthcare facilities, spread across 20 hospital sites in France, along with 2 affiliated institutions. Unicancer is also the leading academic promoter of clinical trials in oncology on a European scale. Recognized as a leader in research in France, the Unicancer network enjoys a worldwide reputation, contributing to one-third of the internationally renowned French publications in oncology (source: bibliometric study/Thomson Reuters). Unicancer is also a pioneer in Real-World Data (RWD) research, with four national RWD platforms launched since 2014, involving around seventy healthcare facilities. These platforms have accumulated over 109,000 registered patients in the ESME program across three indications (metastatic breast cancer, ovarian cancer, and lung cancer), and more than 60,000 in the ODH program, a true observatory for medication and innovation, launched in 2021. Unicancer is also at the forefront of institution-level data mobilization, notably through the Unibase program. >> Follow us: www.unicancer.fr

Media Contact

Daniela Barbieri - d-barbieri@unicancer.fr